DE10021894A1 - Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra - Google Patents
Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethraInfo
- Publication number
- DE10021894A1 DE10021894A1 DE2000121894 DE10021894A DE10021894A1 DE 10021894 A1 DE10021894 A1 DE 10021894A1 DE 2000121894 DE2000121894 DE 2000121894 DE 10021894 A DE10021894 A DE 10021894A DE 10021894 A1 DE10021894 A1 DE 10021894A1
- Authority
- DE
- Germany
- Prior art keywords
- urethra
- prostaglandin
- pharmaceutical preparation
- diagnosis
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Abstract
Description
Die Erfindung betrifft ein pharmazeutisches Präparat zur Diagnose und Behandlung der erektilen Dysfunktion.The invention relates to a pharmaceutical preparation for Diagnosis and treatment of erectile dysfunction.
Die intracavernöse Applikation von vasoaktiven Substan zen zur Diagnostik und Therapie der erektilen Dysfunkti on hat in letzten Zeiten zunehmend an Bedeutung gewon nen. Zu den am häufigsten verwendeten Substanzen gehören das Muskelrelaxans Papaverin als Monosubstanz oder in Kombination mit dem Alphasympatholytikum Phentolamin. The intracavernous application of vasoactive substance zen for the diagnosis and therapy of erectile dysfunction one has become increasingly important in recent times nen. The most commonly used substances include the muscle relaxant papaverine as a single substance or in Combination with the alpha sympatholytic phentolamine.
Heute gibt es ausreichende Erfahrungen mit Prostaglandin E1, das eine Alternative zu Papaverin/Phentolamin dar stellt und sich bei fehlender Priapismogenität und gleichzeitig besserer Wirksamkeit als überlegen erwiesen hat. Ein besonderes Problem der intracavernösen Applika tion vasoaktiver Substanzen ist die schwierige Manipula tion einer Injektion in den Schwellkörper, so daß ein Teil der Patienten die intracavernöse Injektion als unangenehme oder invasive Methode ablehnt. Ein zusätz liches Problem der intrakavernösen Injektion ist die Fibrosen- bzw. Narbenbildung des kavernösen Gewebes als Langzeitschaden.Today there is sufficient experience with prostaglandin E1, which is an alternative to papaverine / phentolamine arises and in the absence of priapismogenicity and proven to be more effective than superior at the same time Has. A particular problem with intra-cavernous applications tion of vasoactive substances is the difficult manipulation tion of an injection in the erectile tissue, so that a Part of the patient considered the intracavernous injection rejects unpleasant or invasive method. An additional The problem with intracavernous injection is Fibrosis or scar formation of the cavernous tissue as Long-term damage.
Deshalb wurde in der Vergangenheit ein Prostaglandin- Präparat in Form eines Stäbchens entwickelt, das mittels einer Spritze in den Meatus urethrae eingebracht wird. Durch Massage wird das Stäbchen dann in der Urethra ver teilt. Nachteil dieses System sind die Notwendigkeit der vorherigen Massage und die Folgen Gefahr der mechani schen Reizung, nämlich Penisschmerzen, Brennen in der Harnröhre, Blutungen und Abschürfungen der Harnröhre.That's why a prostaglandin Prepared in the form of a stick, which by means of a syringe is inserted into the urethral meatus. Massage the rod into the urethra Splits. Disadvantages of this system are the need for previous massage and the consequences risk of mechani irritation, namely penis pain, burning sensation in the Urethra, bleeding and abrasion of the urethra.
Der Erfindung liegt damit die Aufgabe zugrunde, ein pharmazeutisches Präparat zu schaffen, das eine einfache Anwendung ermöglicht, ohne daß die Gefahr einer mechani schen Reizung besteht.The invention is therefore based on the object pharmaceutical preparation to create a simple Application enables without the risk of a mechanical irritation.
Erfindungsgemäß wird diese Aufgabe gelöst durch eine Ausgestaltung des Präparats als Gemisch aus einem ein Anschwellen der Schwellkörper bewirkenden Wirkstoffs und einem bei Applikation in die Harnröhre flüssigen und sodann in dieser ein Gel bildenen Träger. According to the invention, this object is achieved by Design of the preparation as a mixture of one Swelling of the erectile tissue and a liquid when applied to the urethra and then in this gel-forming carrier.
Als Wirkstoffe kommen insbesondere Prostaglandin E1 und Phosphordiesterase-Hemmer (Sildenafilcitrat) in Be tracht.In particular, prostaglandin E1 and Phosphodiesterase inhibitor (sildenafil citrate) in Be dress.
Der Träger kann eine bei Raumtemperatur flüssige und sich bei weiterer Erwärmung zu einem Gel verdickende Substanz sein. Alternativ kann der Träger auch eine Sub stanz sein, die sich bei Kontakt mit der feuchten Mucosa zu einem Gel verdickt.The carrier can be a liquid and liquid at room temperature thickening to a gel when heated further Be substance. Alternatively, the carrier can also be a sub be punched when in contact with the moist mucosa thickened to a gel.
Bei Verwendung eines in Wasser gelöst nicht stabilen Wirkstoffs kommt eine Ausbildung in Betracht, bei der der Wirkstoff als Pulver vorgehalten und dem Wirkstoff erst bei der Applikation Wasser hinzugeben wird. Bei einer solchen Ausbildung kann auch der gelbildende Trä ger als Pulver formuliert sein.When using a non-stable solution dissolved in water Active substance is an education in which the active ingredient held in powder and the active ingredient water is only added during application. At such training can also be the gel-forming Trä be formulated as a powder.
Bei einem Ausführungsbeispiel eines solchen pharmazeuti schen Produkts wird das Prostaglandin E1 an Alpha- Cyclodextrin gebunden und sodann gefriergetrocknet. Zu diesem Pulver wird ein pulvriges Alginsäure-Derivat hin zugegeben, das in wässriger Lösung bei Berührung mit Elektrolyten sich schlagartig zu einem Gel verdickt. Versuche haben gezeigt, daß Wirkstoffdosen von 20 bis 40 µg in 2 ml Trägerlösung geeignet sind.In one embodiment of such a pharmaceutical product, prostaglandin E1 is Cyclodextrin bound and then freeze-dried. To this powder becomes a powdery alginic acid derivative added that in aqueous solution on contact with Electrolytes suddenly thickened into a gel. Tests have shown that drug doses from 20 to 40 µg in 2 ml carrier solution are suitable.
Bei einer Applikation wird diesem Pulvergemisch destil liertes Wasser hinzugegeben, nach der Applikation in die männliche Harnröhre erfolgt der Kontakt mit den Elektro lyten der Schleimhaut der Harnröhre und damit die Gel bildung. Der Wirkstoff wird von der Wandung der Harnröh re aufgenommen und bewirkt sodann über die Blutbahn eine stärkere Durchblutung der Schwellkörper (es versteht sich, daß auch eine Substanz in Betracht kommt, die ein Abfließen von Blut aus dem Schwellkörper behindert und damit zu der erwünschten Blutstauung in den Schwellkör pern führt).When applied, this powder mixture is distilled added water after application in the male urethra comes into contact with the electro lyte the mucous membrane of the urethra and thus the gel education. The active ingredient is from the wall of the urethra re recorded and then causes a via the bloodstream increased blood flow to the erectile tissue (it understands that a substance is also considered, the one Drainage of blood from the erectile tissue and hinders thus to the desired blood congestion in the erectile tissue leads).
Der Träger ist chemisch inert auszubilden, so daß der bei der Ejakulation aus der Harnröhre erfolgende Aus tritt des Substrats in die Vagina der Frau für diese unschädlich ist.The carrier is chemically inert, so that the ejaculation out of the urethra the substrate enters the woman's vagina for this is harmless.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2000121894 DE10021894A1 (en) | 2000-05-05 | 2000-05-05 | Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE2000121894 DE10021894A1 (en) | 2000-05-05 | 2000-05-05 | Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra |
Publications (1)
Publication Number | Publication Date |
---|---|
DE10021894A1 true DE10021894A1 (en) | 2001-11-29 |
Family
ID=7640881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE2000121894 Withdrawn DE10021894A1 (en) | 2000-05-05 | 2000-05-05 | Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE10021894A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR20010100222A (en) * | 2001-04-30 | 2002-12-19 | Ηλιας Κ. Παπαδοπουλος | Pharmaceutical concoction for the diagnosis and therapy of erection problems |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4117249A1 (en) * | 1991-05-27 | 1992-12-03 | Cassella Ag | LINSIDOMIN FOR TREATING ERECTILE DYSFUNCTIONS |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
US5736161A (en) * | 1993-07-21 | 1998-04-07 | Lipotec S.A. | Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it |
-
2000
- 2000-05-05 DE DE2000121894 patent/DE10021894A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4117249A1 (en) * | 1991-05-27 | 1992-12-03 | Cassella Ag | LINSIDOMIN FOR TREATING ERECTILE DYSFUNCTIONS |
US5736161A (en) * | 1993-07-21 | 1998-04-07 | Lipotec S.A. | Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it |
DE4338948A1 (en) * | 1993-11-15 | 1995-05-18 | Carlen Judith | Treating erectile dysfunction without causing side-effects |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR20010100222A (en) * | 2001-04-30 | 2002-12-19 | Ηλιας Κ. Παπαδοπουλος | Pharmaceutical concoction for the diagnosis and therapy of erection problems |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69829672T2 (en) | COMPOSITIONS AND DEVICE FOR GENERATING CHEMICAL NEKROSIS IN THE NUTRITION | |
DE2716386A1 (en) | INTRAVAGINAL CONCEPT PREVENTION DEVICE | |
DE3714074A1 (en) | BASIS FOR MUCUTINE AND PROSTHESISAL PASTE, METHOD FOR THEIR PRODUCTION AND PASTE BASED ON THIS BASE | |
CH638402A5 (en) | METHOD FOR PRODUCING A PHARMACEUTICAL FOR INTRODUCTION IN BODY OPENINGS. | |
DE69822295T2 (en) | USE OF MISOPROSTOL AND / OR MISOPROSTOLIC ACID FOR THE TREATMENT OF EFFECTS OF DISORDER | |
DE1494939B2 (en) | Implantation material for prostheses for the replacement of arteries and other pathways and hollow organs containing body juices and processes for the production thereof | |
DE2802273C3 (en) | Process for the preparation of suppositories from aminoglycidic antibiotics | |
US4600711A (en) | Composition for topical and infusion treatment of wounds and burns | |
WO1999038472A2 (en) | Topical vasodilatory gel composition and methods of use and production | |
DE10021894A1 (en) | Easily applied pharmaceutical composition for diagnosis and treatment of erectile dysfunction, comprises mixture of active agent, e.g. prostaglandin E1, and carrier forming gel in urethra | |
EP0014238A2 (en) | Mucilagenous synthetic lubricant and antifriction agent, especially for the vaginal region, and its use in diagnostic, surgical and treating medicine | |
DE60030319T2 (en) | GEL PREPARATION CONTAINING A SOLVENT OR SUSPENDED ACTIVE, ESPECIALLY FOR THE APPLICATION TO A GARMENT AND MANUFACTURING PROCESS | |
DE69727154T2 (en) | LAND AND SEA TURTLE OILS, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION AND USE THEREOF | |
DE602004011786T2 (en) | TAURIN BROMAMINE FOR THE INHIBITION OF PATHOGENIC BACTERIA AND MUSHROOM GROWTH, AND IN A MICROBICID COMPOSITION | |
Duckworth | The treatment of papillomatosis with podophyllin | |
DE3316597C1 (en) | Gelatinous preparation, and the use thereof as a medicament | |
EP0150248B1 (en) | Means for the treatment and the prophylaxis of uratic and mixed uratic lithiasis | |
DE1667891A1 (en) | New therapeutic compositions with analgesic activity | |
WO1989011276A1 (en) | Acyl carnitine for the treatment and prevention of virus infections | |
DE2213993C3 (en) | Using a solution in gallstone solubilization | |
CH690023A5 (en) | Local medicament for treating damage to cells of nasal mucosal, e.g. due to air pollution or smoking, contains capsaicin to improve mucociliary transport | |
DE627813C (en) | Process for the production of a disinfecting agent for protecting the skin against infections and for healing skin diseases | |
DE2619756A1 (en) | PHARMACEUTICAL PREPARATIONS OF PENICILLIN COMPOUNDS FOR RECTAL USE | |
DE2213275C3 (en) | Process for the preparation of 5,5-diphenylhydantoin sodium solutions as infusion concentrates | |
DE1091287B (en) | Process for the production of stable, aqueous solutions of tyrothricin and subtilin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8139 | Disposal/non-payment of the annual fee |